Drugs used to treat heart failure and high blood pressure may help decrease obesity

June 15, 2013

SAN FRANCISCO-- A type of drug normally used to treat heart failure and high blood pressure helped prevent weight gain and other complications related to a high-fat diet in an animal study. The results were presented today at The Endocrine Society's 95th Annual Meeting in San Francisco.

Weight gain, especially around the waist, and high blood pressure, combine with other abnormalities to form a cluster of diseases known as metabolic syndrome, which increases the risk of heart disease, diabetes and other serious illnesses. With obesity rates climbing in developed countries throughout the world, medical researchers are trying to find new drugs to prevent metabolic syndrome from occurring.

One new and promising approach involves blocking the action of aldosterone and glucocorticoids, hormones synthesized in the adrenal cortex of mammals. These hormones are capable of activating the mineralocorticoid receptors (MRs). MRs are ligand-activated transcription factors that play a key role in many physiological and pathological processes occurring in several tissues and organs, including kidney, heart and adipose tissue.

Drugs that prevent MRs from reacting to their ligands are known as MR antagonists. In this study, investigators examined, in mice fed a high-fat diet, the effects of drospirenone and spironolactone, two MR antagonists currently used in clinical practice that have been previously shown to modulate adipocyte differentiation in vitro.

They found that the drugs had several benefits, including helping to prevent weight gain and to increase the number of energy-burning fat cells. Animals that received MR antagonists combined with a high-fat diet exhibited more brown fat cells interspersed within white fat tissue, compared to untreated controls. The so-called good kind of fat, brown fat cells actually burn energy to help prevent weight gain, while white fat does the opposite, storing energy as more fat cells.

In order to evaluate the expansion of brown adipose tissue, the investigators also used special imaging tests to measure the percentage of water in fat cells which, at high levels, indicates the presence of brown fat.

In addition, these MR antagonists were effective in reducing the high levels of blood glucose related to impaired glucose tolerance, which can be a precursor to diabetes.

"These data open new unexpected applications of MR antagonists in the treatment of obesity and its metabolic complications, since their use in animal models reverses the metabolic dysfunction induced by a high-fat diet, promoting the activation of brown-like fat in classical white fat depots," said study lead author Andrea Armani, Ph.D., a post-doctoral fellow in obesity research. "Indeed, MR antagonism has promise as a novel approach to treat metabolic syndrome."

The study was coordinated by Massimiliano Caprio, MD, PhD, at the IRCCS San Raffaele Pisana Research Center in Rome, Italy. Previous research by Dr. Caprio's laboratory showed that blocking MR expression in human and animal precursor fat cells prevented them from developing further. These findings led the investigators to design the current study to examine the effects of MR antagonists on adipose tissue and glucose metabolism under obesogenic conditions.

The IRCCS San Raffaele Pisana (Ricerca Corrente); the University of Rome; and the Italian Ministry of Foreign Affairs supported the study.
-end-
Founded in 1916, The Endocrine Society is the world's oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, The Endocrine Society's membership consists of over 16,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Chevy Chase, Maryland. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter.

The Endocrine Society

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.